The Guideline for Diagnosis and Management of Chronic Obstructive Pulmonary Disease in 2001 (‘the new guideline’ in the following passages) has been released recently. Lishutong (Levosalbutamol Hydrocloride Nebuliser Solution), a product Joincare Pharmaceutical Group Industry Co., Ltd (Joincare), is the first authorized β2 adrenoceptor agonist. The medicine was recommended as the first-line treatment. All of these is a sign that the high-standard inhale preparation formally join in the market competition.

According to the data, chronic obstructive pulmonary diseases has become one of the common chronic diseases as hypertension and diabetes, and the number of its domestic patients is reaching to 100 million. All of these arise a huge challenge to the public health system in China. Inhale preparation can directly affect the target organs. Therefore, it works more effectively, but has less by-effect. For these advantages, the medicine is recommended as the prior treatment for chronic obstructive pulmonary diseases. Provisionally, most of the market share in China is dominated by few international pharmaceutical companies from Europe, America and Japan. In recent years, responding to the call of the nation, Baoguo Zhu, president of Joincare, has planned the development of respiratory medicine. Aiming to break the monopoly of the international pharmaceutical companies, Zhu gave a priority to breaking the technical barriers of the research and production of inhale preparation. Zhu’s plan has brought high-standard Chinese preparations into the market in order to change the competitive situation of the market and also provide a new option for the patients.

Lishutong (Levosalbutamol Hydrocloride Nebuliser Solution) was included in the Medicine List of National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance and Maternity Insurance in 2020 (‘the national medical insurance list in the following passages) so as to meet the requirement of medicine access. The recommendation by the new guideline means that Lishutong is recognized by the clinical first-line. Also, it has solved the ‘one last mile’ to the rational clinical use of drugs.

Nowadays, Joincare has a leading role of the investment and process of research and development. Joincare has put many products into the market, including Wushu (Budesonide Suspension for inhalation), Liwuan(Ipratropium Bromide Solution for Inhalation), Indacaterol Maleate Powder for Inhalation, a developing product of Joincare. Joincare’ products have covered all kinds of inhale medicines, and this proves the rise of the domestic market in medical field and the huge potential of the market.

Joincare will unyieldingly keep innovation as its center, and drive the enterprises to make further development. The company considers the people’s lives and health as the most important thing, and provides Chinese patients with high-standard inhale preparation. Moreover, it also benefits all domestic patients suffering chronic obstructive pulmonary diseases, and contributes to ‘Healthy China 2030’.